logo-loader
HealthMedical technology & services
viewLombard Medical Technologies

Lombard Medical Technologies says first US Aorfix treatments go well

medical_100x72.jpg

Lombard Medical Technologies (LON:LMT) revealed the first US patients have been successfully treated with Aorfix, its flexible stent graft used to treat ruptures to the main artery.

Aorfix was approved by the US Food & Drug Administration (FDA) for commercial sale in the US in February 2013, prompting 30% spike in the share price at the time for a stock that had already doubled in price over the previous year.

Aorfix is the only endovascular stent graft with approved labelling for use in more challenging cases with neck angulations greater than 60 degrees.

The first US cases using Aorfix included patients with aortic neck angles significantly greater than 60 degrees that would have previously required more invasive open surgical abdominal aortic aneurysm (AAA) repair or "off label" use of an alternative device not designed to treat patients with this level of tortuosity in the aorta.

All patients are doing well following the procedures.

Simon Hubbert, chief executive officer of Lombard Medical said: "Since receiving US FDA approval, the company has invested in the right people and worked diligently to ensure we have the commercial infrastructure and processes in place to become a significant player in the AAA market in the United States."

Dr Victor Weiss, a vascular surgeon who performed some of the operations, said: “Based on my initial experience with Aorfix, I believe its ease of use and unique design will provide us with an important new tool to ensure the effectiveness of endovascular treatment of AAAs."

Dr Sachinder Hans, MD of Henry Ford Hospital in Detroit, said: "I was particularly impressed by how Aorfix conformed to a very challenging anatomy. This patient had several health issues that existed prior to the procedure, including poor renal function and heavy calcium deposits, but we had a very successful outcome due to our ability to address the AAA in a minimally invasive fashion.

"Aorfix provides a new and important addition to the armamentarium of physicians working with patients with AAAs."

Quick facts: Lombard Medical Technologies

Price: 0 0

AIM:LMT
Market: AIM
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Blue Star Capital shifts focus to eSports as it invests in...

Blue Star Capital plc's (LON:BLU) Tony Fabrizi tells Proactive London they're to raise up to £900,000 to fund a shift of direction into the esports arena. Blue Star will invest about £150,000 each into six esports businesses spread throughout the world in the UK, USA, Canada, Australia and...

8 minutes ago

2 min read